An increased number of low-density lipoprotein particles (LDL-P) is a common feature of patients with Metabolic syndrome (MetS). Increasing the size of these particles is one of the primary therapeuti Show more
An increased number of low-density lipoprotein particles (LDL-P) is a common feature of patients with Metabolic syndrome (MetS). Increasing the size of these particles is one of the primary therapeutic and dietary interventions goals. However, genetic variability, like single nucleotide polymorphisms (SNPs), modulate the response to dietary strategies. Therefore, we hypothesise that the presence of SNPs in genes associated with MetS may modulate the effect of a dietary intervention on the size of LDL-P. This was a before-and-after clinical study conducted with 146 participants with MetS. The participants underwent a lifestyle intervention for 10 weeks. At baseline the presence of SNPs associated with MetS were determined. Anthropometric, biochemical, hormonal parameters, and lipoprotein analysis were taken before and after the intervention. Results revealed that the common homozygous ATP-binding cassette transporter A1 (ABCA1) genotype was associated with a decreased LDL-C concentration. However, after adjusting for sex, age and baseline weight, polymorphisms in the fat mass and obesity-associated (FTO) gene, the peroxisome proliferator-activated receptor (PPARÎł), and the apolipoprotein E (APOE) gene were associated with a better response to the intervention in terms of increasing LDL-P size. Our results revealed changes in LDL-P size associated with polymorphisms in the APOE, FTO and PPARÎł genes in response to the dietary intervention. These results highlight the importance of genetic factors in personalized nutritional strategies aimed at improving cardiovascular risk in patients with MetS. NCT03611140, www. gov. Show less